Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 18, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 200,000 ordinary shares of 25 pence each.
- Purchase Price: 1,488.43 pence per share.
- Total Treasury Shares Held: 179,751,678 shares following the transaction.
- Shares in Issue: 5,804,302,038 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company acquired 200,000 shares on July 18, 2006, which are now held in Treasury. No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase or subscribe for securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 200,000 share repurchase (200,000 shares x 1,488.43 pence).
- Confirm the updated share capital structure: 5,804,302,038 shares in issue versus 179,751,678 shares in Treasury.
- Review the Annual General Meeting minutes from May 17, 2006, to understand the full scope of the share buyback authority granted.
- Note that this filing does not contain quarterly or annual financial performance data; refer to Form 20-F for comprehensive financial results.